Want to see JP:7792 full AI Analyst Report?
Colan Totte.Co.,Ltd. (7792) AI Stock Analysis
Colan Totte.Co.,Ltd.
(TSE/TYO:7792)
Colan Totte Co., Ltd. presents an outstanding investment profile driven by exceptional profitability, a nearly debt-free balance sheet, and a highly attractive valuation. The stock trades at a compelling P/E ratio of 9.7 while offering a solid dividend yield, backed by a strong return on equity. Technical indicators point to steady upward momentum across key moving averages, reinforcing the stock's overall strength and minimizing immediate downside risk.
Colan Totte.Co.,Ltd. (7792) vs. iShares MSCI Japan ETF (EWJ)
- Market Cap
- JPY 13.08B
- Dividend Yield
- 3.52%
- Average Volume (3M)
- 14.32K
- Price to Earnings (P/E)
- 9.1
- Beta (1Y)
- 0.53
- Revenue Growth
- 33.43%
- EPS Growth
- 12.57%
- Country
- Japan
- Employees
- 104
- Sector
- General
- Sector Strength
- 55
- Industry
- Medical - Devices
Colan Totte.Co.,Ltd. Business Overview & Revenue Model
Company Description
Colan Totte Co., Ltd., established in Osaka, Japan, in 1997, operates as an international firm specializing in the development and global distribution of therapeutic devices under its proprietary Colantotte brand. The company's diverse product portfo...
How the Company Makes Money
null
Colan Totte.Co.,Ltd. Financial Statement Overview
Summary
Exceptional financial profile featuring robust margins (19.2% net profit), an unlevered balance sheet (0.002 D/E ratio), and strong free cash flow generation, reflecting excellent operational efficiency.
Income Statement
92Very PositiveBalance Sheet
96Very PositiveCash Flow
84Very Positive| Breakdown | TTM | Sep 2025 | Sep 2024 | Sep 2023 | Sep 2022 | Sep 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 8.02B | 6.92B | 5.94B | 5.41B | 4.66B | 3.71B |
| Gross Profit | 5.46B | 4.66B | 3.97B | 3.45B | 3.04B | 2.46B |
| EBITDA | 2.06B | 1.90B | 1.57B | 1.10B | 1.02B | 691.13M |
| Net Income | 1.35B | 1.33B | 1.02B | 645.02M | 610.45M | 420.50M |
Balance Sheet | ||||||
| Total Assets | 7.18B | 6.74B | 5.43B | 4.91B | 4.13B | 3.62B |
| Cash, Cash Equivalents and Short-Term Investments | 2.11B | 2.18B | 1.76B | 1.79B | 1.34B | 1.55B |
| Total Debt | 8.05M | 12.90M | 8.69M | 1.27M | 270.48M | 439.84M |
| Total Liabilities | 1.62B | 1.57B | 1.32B | 1.64B | 1.38B | 1.38B |
| Stockholders Equity | 5.55B | 5.17B | 4.11B | 3.27B | 2.75B | 2.24B |
Cash Flow | ||||||
| Free Cash Flow | 1.06B | 728.70M | 357.26M | 867.34M | 75.48M | 597.37M |
| Operating Cash Flow | 1.48B | 998.35M | 883.77M | 955.70M | 148.09M | 637.27M |
| Investing Cash Flow | -471.40M | -303.40M | -736.91M | -83.80M | -80.38M | -51.45M |
| Financing Cash Flow | -654.18M | -272.18M | -180.15M | -410.10M | -274.23M | 452.40M |
Colan Totte.Co.,Ltd. Technical Analysis
Price Trends
Market Momentum
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For JP:7792, the sentiment is Negative. The current price of 1421.00 is below the 20-day moving average (MA) of 1461.40, below the 50-day MA of 1444.63, and above the 200-day MA of 1412.99, indicating a neutral trend. The MACD of -3.67 indicates Positive momentum. The RSI at 38.13 is Neutral, neither overbought nor oversold. The STOCH value of 12.27 is Positive, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for JP:7792.
Colan Totte.Co.,Ltd. Peers Comparison
Overall Rating
JP:779290Outperform
JP:518770Outperform
JP:652358Neutral
JP:454950Neutral
JP:760047Neutral
JP:684946Neutral
Financial Indicators
| Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
| 90Outperform | JPY 13.12B | 9.14 | ― | 3.52% | 33.43% | 12.57% | |
| 70Outperform | JPY 10.13B | 16.63 | ― | 4.27% | 3.38% | -52.61% | |
| 58Neutral | JPY 180.17B | 19.39 | 5.76% | 2.99% | 3.04% | -19.26% | |
| Sector * | 55Neutral | $6.65B | 3.83 | -15.92% | 6.20% | 10.91% | 7.18% |
| 50Neutral | JPY 76.06B | 39.82 | ― | 2.59% | 3.92% | -52.01% | |
| 47Neutral | JPY 15.22B | -67.86 | ― | 2.94% | -6.64% | 67.08% | |
| 46Neutral | JPY 265.01B | 18.99 | ― | 2.01% | 1.43% | 1.86% |
* General Sector Average
Performance Comparison
| Show on chart | Ticker | Company Name | Price | Change | % Change |
|---|---|---|---|---|---|
| JP:7792 | Colan Totte.Co.,Ltd. | 1421.00 | -27.39 | -1.89% | |
| JP:6523 | PHC Holdings Corp. | 1405.00 | 412.43 | 41.55% | |
| JP:4549 | Eiken Chemical Co., Ltd. | 2238.00 | -95.34 | -4.09% | |
| JP:5187 | Create Medic Co., Ltd. | 1123.00 | 146.22 | 14.97% | |
| JP:6849 | Nihon Kohden Corporation | 1589.50 | -157.88 | -9.04% | |
| JP:7600 | Japan Medical Dynamic Marketing, Inc. | 568.00 | 88.50 | 18.46% |
Colan Totte.Co.,Ltd. Corporate Events
Colan Totte Lifts Sales, Guidance and Dividend on Strong First‑Half Earnings
Colan Totte reported robust non‑consolidated results for the six months ended March 31, 2026, with net sales rising 34.1% year on year to ¥4.33 billion and operating profit up 18.2% to ¥1.12 billion, while profit edged up 3.3% to ...
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.
Date of analysis: Aug 04, 2026